Proactive Investors - Run By Investors For Investors

Faron Pharma: Japanese data bears out earlier study result

Chief executive Dr Markku Jalkanen pointed out: “It appears likely that corticosteroid use diminished the treatment benefit of Traumakine in ARDS patients in the Japanese Phase III study."
Faron Pharma: Japanese data bears out earlier study result
The Faron drug did not reduce mortality or increase the number of ventilator-free survival days

Faron Pharmaceuticals Ltd (LON:FARN) said a separate Japanese study effectively confirmed the results of an earlier phase III trial of its Traumakine drug for people with acute respiratory distress syndrome (ARDS).

In other words, it did not reduce mortality or increase the number of ventilator-free survival days when compared to placebo.

But as chief executive, Dr Markku Jalkanen, pointed out: “It appears likely that corticosteroid use diminished the treatment benefit of Traumakine in ARDS patients in the Japanese Phase III study.

“Unfortunately, the use of steroids has become a standard in ARDS despite any evidence base and this requires critical reassessment, as the use of steroids appears to worsen outcomes in certain ARDS subgroups."

View full FARN profile View Profile

Faron Pharmaceuticals Ltd Timeline

Related Articles

A woman with severe depression
April 25 2019
The New York clinical-stage biopharmaceutical company has several drugs in the pipeline capable of generating hefty revenue
lab worker
May 20 2019
Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology
genedrive device
Tue
Here we take a closer look at Genedrive PLC (LON:GDR)

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use